Impact of new antiretroviral combination therapies on human immunodeficiency virus in infected patients. Study of 807 patients;Eficacia del tratamiento antirretroviral en pacientes con infección por el virus de la inmunodeficiencia humana. Estudio de 807 pacientes

Medicina Clinica

Volumn 115, Issue 13, 2000, Pages 481-486

  Alonso Socas, María Del Mar ^a   Gómez Sirvent, Juan Luis ^a   Fernández, Francisco Santolaria ^a   Moreno, Fermín Rodríguez ^a   Essardas, Hiroo ^a   Rodríguez, Eva Rodríguez ^a   Gaspar, Melchor Rodríguez ^a   Castellón, Carmen Durán ^a   Valls, Remedios Alemán ^a   Reimers, Emilio González ^a  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

Author keywords

Antiretroviral therapy; HIV infection

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG POTENCY; HOSPITAL ADMISSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; SURVIVAL;

EID: 0342935985     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(00)71601-0     Document Type: Article

References (32)

1. Jones JI, Hanson DL, Chu SY, Ciesielski CA, Kaplan JE, Ward JW. Toxoplasmic encephalitis in HIV-infected persons: risk factors and trends. AIDS 1996; 10: 1393-1399.
2. Graham NM, Zeger SL, Park LP, Phair JP, Detels R, Vermund SH Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS. The Multicenter AIDS Cohort Study. Lancet 1991; 338: 265-269.
3. Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ 1997; 315: 1194-1199.
4. Palella F, Delaney MS, Moorman AC, Loveless MO, Fuhrer J, Satten GA et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 865-860.
5. Hogg R, O'Shaughnessy M, Gataric N, Yip B, Craib K, Schetchter MT et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet 1997; 349: 1294.
6. Detels R, Muñoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with knoww HIV infection duration. JAMA 1998; 280: 1497-1503.
7. Hogg R, Heath K, Yip B, Craib KJ, O'Shaughnessy MV, Schechter MT et al. improved survival among HIV infected individuals following initiation of antiretroviral therapy. JAMA 1998; 279: 450-454.
8. Tassie JM, Lancar R, Delomeaux J, Grabar S, Bentata M, Costagliola D. Time of AIDS according to antiretroviral regimen availability: results from de French hospital database on HIV. Seventh European Conference on Clinical Aspects and treatment of HIV-infection. [Resumen 216]. Lisboa (Portugal); 23-27 de octubre de 1999.
9. Weight changes during HIV infection: relationship with use of proteasa inhibitors and survival: results from the EUROSIDA study. Seventh European Conference on Clinical Aspects and treatment of HIB-infection [resumen 480] Lisboa (Portugal), 23, 27 de octubre de 1999.
10. García de Olalla P, Caylà JA, Brugal MT, Galdós H, Jansà JM, Clos R. Evolución de la mortalidad y supervivencia del sida en Barcelona (1981-1997). Med Clin (Barc) 1999; 113: 169-170.
11. Cifford DB, Yiannoutsos C, Glicksman M, Simpson DM, Singer EJ, Piliero PJ et al. HAART improves prognosis in HIV-associates progressive multifocal leukoencephalopathy. Neurology 1999; 52: 623-625.
12. Albrecht H, Hoffman C, Degen O, Stoehr A, Plettenberg A, Mertenskotter T et al. Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopaty. AIDS 1998; 12: 1149-1154
13. Berenguer J, Blazquez R, Ocana I, Lozano F. Infections by Candida and Cryptococci. Enferm Infecc Microbiol Clin 1998; 16 (supl 1): 29-35.
14. Walsh J, Jones C, Barnes E, Gazzard BC, Mitchell SM. Increasing survival in AIDS patients with cytomegalovirus retinitis treated with combination antiretroviral therapy including HIV protease inhibitors. AIDS 1998; 12: 613-618.
15. Brodt HR, Kamps S, Gute P, Knupp B, Staszewski S, Helm EB. Changing incidence of AIDS-definig illnesses in the era of antiretroviral combination therapy. AIDS 1997; 11: 1731-1738.
16. Alonso MM, García F, Mallolas J, Soriano A, Ortega M, Miró JM et al. Criptococosis diseminada en pacientes con sida. Factores pronósticos de mala evolución. Med Clin (Barc) 1999; 112: 401-405.
17. García Vázquez E, De Górgolas Hernández M, García Delgado R, Fernández Guerrero ML. Suspensión de profilaxis frente a neumonía por Pneumocystis carinii en pacientes con tratamiento antirretroviral combinado eficaz. Estudio de 85 casos. Med Clin (Barc) 1999; 113: 89-90.
18. Jouan M. Opportunistic infections in patients under highly concentrated antiretroviral therapy. J Infect Dis 1998; 177: 1182-1187.
19. Aboulafia DM. Regression of acquired immunodeficiency syndrome-related pulmonary Kaposi's sarcoma after highly active antiretroviral therapy. Mayo Clin Proc 1998; 73: 439-443.
20. Ferrando S, Van Gorp W, McElhiney M, Goggin K, Sewell M, Rabkin J et al. Highly active antiretroviral treatment in HIV infection: benefits for neuropsychological function. AIDS 1998; 12: F65-F70.
21. Mouton Y, Alfandari S, Valette M, Cartier F, Dellamonica P, Humbert G et al. Impact of protease inhibitors on AIDS-defining events and hospitalizatins in 10 French AIDS reference centres. Federation National des Centres de Lutte contre le SIDA. AIDS 1997; 11: F101-F105.
22. De Luca A, Antinori A, Ortona I. Antiretroviral therapy and improving AIDS survival. JAMA 1998; 279: 1874-1875.
23. Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Br Med J 1997; 315: 1194-1199.
24. Van Haastrecht HJ, Van den Hoek AJ, Coutinho RA. High mortality among HIV-infected injecting drug users without AIDS diagnosis: implications for HIV infection epidemic modellers? AIDS 1994; 8: 363-366.
25. Brettle RP, Chiswick A, Bell J, Bussuttil A, Wilson A, Povey S et al. Pre-AIDS death in HIV infection related to intravenous drug use. QJM 1997; 90: 617-629.
26. Prins M, Hernández Aguado IH, Brettle RP, Robertson JR, Broers B, Carre N et al. Pre-AIDS mortality from natural causes associated with HIV disease progression: evidence from the European Seroconverter Study among injecting drug users. AIDS 1997; 11: 1747-1756.
27. Muga R, Egea JM, Navio M, Sirera G, Vall M, Tor J. Mortalidad en una cohorte de usuarios de drogas por via intravenosa antes de la indroducción de la terapia VIH potente. Med Clin (Barc) 1999; 112: 721-725.
28. a ed.). Barcelona: Masson S.A., 1986; 50-73.
29. th Conference on Retroviruses and Opportunistic infections, 31 enero-4 febrero de 1999.
30. th World AIDS Conference [resumen]: 28 junio-3 julio de 1998.
31. th World AIDS Conference, 28 junio-3 julio de 1998.
32. CEESCAT. Vigilancia epidemiològica de la sida a Catalunya. Situació fins al 30 de juny de 1997. Butlletí Epidemiòlogic de Catalunya 1997; XVIII: 112-122.